While the parties entered into a definitive agreement, disclosed after US financial markets closed Monday, they said they expect to complete the transaction by Friday.

Rhythmia develops advanced mapping and navigation software for use in cardiac catheter ablations, a way to treat abnormal heart rhythms, and other electrophysiology procedures, including atrial fibrillation and atrial flutter. If its technology is approved by regulators in the United States and Europe, Boston Scientific said it expects to begin a limited market launch of the Rhythmia technology used with Boston Scientific’s catheters next year and full market launch in 2014.

BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.

Thanks & Welcome to Globe.com

You now have unlimited access for the next two weeks.

BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.